Akebia Therapeutics Inc (AKBA)
1.37
+0.01
(+0.74%)
USD |
NASDAQ |
Apr 23, 16:00
1.36
-0.01
(-0.73%)
After-Hours: 04:50
Akebia Therapeutics Cash from Operations (TTM): -23.38M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -23.38M |
September 30, 2023 | -75.76M |
June 30, 2023 | -34.78M |
March 31, 2023 | -69.07M |
December 31, 2022 | -73.15M |
September 30, 2022 | -81.28M |
June 30, 2022 | -171.36M |
March 31, 2022 | -203.84M |
December 31, 2021 | -252.96M |
September 30, 2021 | -220.94M |
June 30, 2021 | -191.91M |
March 31, 2021 | -91.54M |
December 31, 2020 | -110.39M |
September 30, 2020 | -171.74M |
June 30, 2020 | -133.52M |
March 31, 2020 | -209.10M |
December 31, 2019 | -257.44M |
September 30, 2019 | -239.00M |
June 30, 2019 | -262.46M |
March 31, 2019 | -215.09M |
December 31, 2018 | -97.49M |
Date | Value |
---|---|
September 30, 2018 | -40.17M |
June 30, 2018 | -82.33M |
March 31, 2018 | -66.96M |
December 31, 2017 | -56.16M |
September 30, 2017 | 55.89M |
June 30, 2017 | 82.26M |
March 31, 2017 | 30.94M |
December 31, 2016 | 57.91M |
September 30, 2016 | -60.68M |
June 30, 2016 | -41.46M |
March 31, 2016 | -26.63M |
December 31, 2015 | -52.41M |
September 30, 2015 | -38.70M |
June 30, 2015 | -35.27M |
March 31, 2015 | -29.82M |
December 31, 2014 | -27.48M |
September 30, 2014 | -23.19M |
June 30, 2014 | -20.52M |
March 31, 2014 | -15.81M |
December 31, 2013 | -11.33M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-262.46M
Minimum
Jun 2019
-23.38M
Maximum
Dec 2023
-151.24M
Average
-171.36M
Median
Jun 2022
Cash from Operations (TTM) Benchmarks
Ocugen Inc | -62.05M |
Aquestive Therapeutics Inc | -6.38M |
SELLAS Life Sciences Group Inc | -31.41M |
Protagonist Therapeutics Inc | -70.24M |
Stoke Therapeutics Inc | -81.07M |